Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Expression System:
HEK293
Purity:
> 95% as determined by Bis-Tris PAGE,> 95% as determined by HPLC
Form:
Lyophilized
Sequence:
Pro20-Pro278 with site mutations
Target:
CD19
Immobilized Human UltraPro Mutant CD19, His Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for FMC63, mFc Tag with the EC50 of 9.5ng/ml determined by ELISA.
Immobilized Human UltraPro Mutant CD19, His Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for Coltuximab, hFc Tag with the EC50 of 4.9ng/ml determined by ELISA.
Immobilized Human UltraPro Mutant CD19, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Denintuzumab, hFc Tag with the EC50 of 3.3ng/ml determined by ELISA.
Immobilized Human UltraPro Mutant CD19, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Inebilizumab, hFc Tag with the EC50 of 3.8ng/ml determined by ELISA.
The purity of Human UltraPro Mutant CD19 is greater than 95% as determined by SEC-HPLC.
Human UltraPro Mutant CD19 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Loaded Coltuximab on ProA-Biosensor can bind Human UltraPro Mutant CD19, His Tag with an affinity constant of 9.48 nM as determined in BLI assay (Gator Prime).
Loaded FMC63 on MFC-Biosensor can bind Human UltraPro Mutant CD19, His Tag with an affinity constant of 3.80 nM as determined in BLI assay (Gator Prime).
Loaded Inebilizumab on ProA-Biosensor can bind Human UltraPro Mutant CD19, His Tag with an affinity constant of 3.97 nM as determined in BLI assay (Gator Prime).
Loaded Denintuzumab on ProA-Biosensor can bind Human UltraPro Mutant CD19, His Tag with an affinity constant of 8.05 nM as determined in BLI assay (Gator Prime).
* VAT and and shipping costs not included. Errors and price changes excepted